Showing results (451-460 of 537) with videos related to

Sort By:
Pageof 54
Neurology|August 17, 2022
Efficacy of Ubrogepant in the Acute Treatment of Migraine With Mild Pain vs Moderate or Severe PainRichard B Lipton, David W Dodick, Peter J Goadsby, et al.
Cephalalgia : an International Journal of Headache|December 9, 2024
Weight loss with atogepant during the preventive treatment of migraine: A pooled analysisB Lee Peterlin, Dale S Bond, Jessica Ailani, et al.
Cephalalgia : an International Journal of Headache|October 27, 2010
Randomized, controlled trial of telcagepant over four migraine attacksAndrew P Ho, Carl Gh Dahlöf, Stephen D Silberstein, et al.
Cephalalgia : an International Journal of Headache|March 9, 2011
Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraineDavid J Hewitt, Sheena K Aurora, David W Dodick, et al.
Lancet (London, England)|November 28, 2008
Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trialTony W Ho, Michel D Ferrari, David W Dodick, et al.
Neurology|August 28, 2024
Effect of Ubrogepant on Patient-Reported Outcomes When Administered During the Migraine Prodrome: Results From the Randomized PRODROME TrialRichard B Lipton, Andrea M Harriott, Julia Y Ma, et al.
Headache|October 13, 2022
Post hoc analysis of clinical trial data and pharmacokinetic data to assess wearing-off of erenumab within monthly treatment cycleDavid W Dodick, Andrew M Blumenfeld, Rashmi B Halker Singh, et al.
Headache|April 1, 2022
Challenges and complexities in designing cluster headache prevention clinical trials: A narrative reviewDavid W Dodick, Peter J Goadsby, Messoud Ashina, et al.
JAMA Network Open|June 8, 2022
Rates of Response to Atogepant for Migraine Prophylaxis Among Adults: A Secondary Analysis of a Randomized Clinical TrialRichard B Lipton, Patricia Pozo-Rosich, Andrew M Blumenfeld, et al.
Cephalalgia : an International Journal of Headache|February 14, 2020
Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: Results from 3-month double-blind treatmentDavid W Dodick, Peter J Goadsby, Christian Lucas, et al.
Pageof 54